Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by Ninety One UK Ltd

Ninety One UK Ltd grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 12.2% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 569,045 shares of the medical research company's stock after acquiring an additional 61,655 shares during the quarter. Ninety One UK Ltd owned about 0.15% of Thermo Fisher Scientific worth $283,157,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Financial Counselors Inc. increased its stake in Thermo Fisher Scientific by 5.4% during the first quarter. Financial Counselors Inc. now owns 84,545 shares of the medical research company's stock worth $42,070,000 after acquiring an additional 4,348 shares during the last quarter. TD Private Client Wealth LLC increased its stake in Thermo Fisher Scientific by 21.4% during the first quarter. TD Private Client Wealth LLC now owns 7,550 shares of the medical research company's stock worth $3,757,000 after acquiring an additional 1,332 shares during the last quarter. Capital Advisors Inc. OK grew its stake in shares of Thermo Fisher Scientific by 0.8% in the first quarter. Capital Advisors Inc. OK now owns 100,324 shares of the medical research company's stock valued at $49,921,000 after buying an additional 830 shares in the last quarter. Heritage Wealth Management Inc. grew its stake in shares of Thermo Fisher Scientific by 10.5% in the first quarter. Heritage Wealth Management Inc. now owns 684 shares of the medical research company's stock valued at $340,000 after buying an additional 65 shares in the last quarter. Finally, Roffman Miller Associates Inc. PA grew its stake in shares of Thermo Fisher Scientific by 2.5% in the first quarter. Roffman Miller Associates Inc. PA now owns 37,402 shares of the medical research company's stock valued at $18,611,000 after buying an additional 898 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the sale, the executive vice president owned 23,167 shares of the company's stock, valued at $9,960,188.31. The trade was a 1.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.33% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on TMO shares. Royal Bank Of Canada lowered their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Wednesday, May 21st. Wells Fargo & Company reduced their price target on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a report on Thursday, April 24th. Evercore ISI reduced their price target on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a report on Tuesday. Finally, Barclays reduced their price target on Thermo Fisher Scientific from $475.00 to $450.00 and set an "equal weight" rating for the company in a report on Tuesday, June 24th. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and an average price target of $603.05.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock traded up $7.95 on Tuesday, reaching $426.65. 2,620,440 shares of the company were exchanged, compared to its average volume of 1,979,128. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. The company's 50-day moving average is $409.13 and its two-hundred day moving average is $478.65. The firm has a market cap of $161.06 billion, a price-to-earnings ratio of 25.02, a P/E/G ratio of 2.28 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $5.10 by $0.05. The firm had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The firm's revenue was up .2% compared to the same quarter last year. During the same period last year, the firm earned $5.11 EPS. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.40%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's payout ratio is currently 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.